Status:
COMPLETED
Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian Patients
Lead Sponsor:
Mohamed Saleh Fayed
Conditions:
Acute Coronary Syndrome
Hypertension
Eligibility:
All Genders
18-75 years
Brief Summary
Beta-blockers represent a cornerstone for the treatment of coronary artery disease (CAD). Their protective effect is based on the negative inotropic and chronotropic features, which have been tested i...
Eligibility Criteria
Inclusion
- Beta-blockers naïve patients
- Patients been on beta-blocker therapy for at least 4 weeks.
- Age (18-75) Years old.
Exclusion
- Non-Egyptians.
- Kidney failure of any stage.
- Liver failure of any stage.
- Malignancy.
- Pregnancy.
- HR \< 55 beats/min (in the absence of b-blocker therapy).
- Presence of a cardiac pacemaker.
Key Trial Info
Start Date :
May 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04900545
Start Date
May 5 2021
End Date
August 1 2021
Last Update
December 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals.
Cairo, Cairo Governorate, Egypt, 12234